Anonymous
Guest
Anonymous
Guest
JnJ in all of their wisdom has started the move towards replacement of the successful biotech group and replacement by the poorly performing Pharma sector. In keeping with corporate credo and vision of senior leadership, the move should complete the move in making JnJ the laughing stock of the industry. This is a very interesting direction. Take the group that has failed at everything and have them replace a group that has never failed. This makes me happy I sold my stock this year. As bio continues to overtaken by Pharma flunkies, the bio brains continues to be pushed out. JnJ is running out of OCs to pay the bills.